Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Antiviral drug discovery and development / / editors, Xinyong Liu [and three others]
| Antiviral drug discovery and development / / editors, Xinyong Liu [and three others] |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (364 pages) |
| Disciplina | 615.7924 |
| Collana | Advances in experimental medicine and biology |
| Soggetto topico |
Antiviral agents - Development
Antiretrovirals Farmacologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-16-0267-0 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910492153003321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral drug strategies / / edited by Erik De Clercq
| Antiviral drug strategies / / edited by Erik De Clercq |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2011 |
| Descrizione fisica | 1 online resource (428 p.) |
| Disciplina | 615.7/924 |
| Altri autori (Persone) | De ClercqErik |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico | Antiviral agents - Development |
| ISBN |
1-283-14091-8
9786613140913 3-527-63596-3 3-527-63597-1 3-527-63595-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antiviral Drug Strategies; Contents; List of Contributors; Preface; A Personal Foreword; 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug; 1.1 Introduction: The Prehistory; 1.2 Key Events in Antiviral Drug Development; 1.3 Antiviral Drugs: Current State of the Art; 1.4 Antiviral Drugs Active against Herpesviruses (i.e., HSV, VZV, and so on); 1.5 Antiviral Drugs Active against Retroviruses (HIV); 1.6 Antiviral Drugs Active against Hepatitis B Virus; 1.7 Antiviral Drugs Active against DNA Viruses at Large
1.8 Antiviral Drugs for Influenza A Virus Infections1.9 Antiviral Drugs for Hepatitis C Virus; 1.10 Antiviral Drugs for Poxviruses (i.e., Variola, Vaccinia, and so on); 1.11 Further Options to Treat Virus Infections; 1.12 Conclusions; References; 2 Inhibition of HIV Entry; 2.1 Introduction; 2.2 The HIV Glycoproteins; 2.2.1 Structure of the HIV-1 Glycoprotein gp120; 2.2.2 Structure of the HIV-1 Transmembrane Glycoprotein gp41; 2.3 Mechanism of HIV Entry; 2.3.1 Virus Attachment; 2.3.2 Coreceptors: Virus Tropism and Infectivity; 2.3.3 Virus-Cell Fusion; 2.3.4 Endocytosis of HIV 2.4 Inhibition of HIV Entry2.4.1 Inhibitors of Virus Attachment; 2.4.1.1 Polyanions as Inhibitors of HIV Attachment; 2.4.1.2 Small-Molecule Inhibitors of the gp120-CD4 Interaction; 2.4.2 Postattachment Inhibitors; 2.4.3 CCR5 Antagonists; 2.4.3.1 Maraviroc; 2.4.3.2 Vicriviroc; 2.4.3.3 Pro-140; 2.4.3.4 Resistance to CCR5 Antagonists; 2.4.4 CXCR4 Antagonists; 2.4.5 Inhibitors of HIV Fusion: Enfuvirtide; 2.5 Concluding Remarks; References; 3 Targeting Integration Beyond Strand Transfer: Development of Second-Generation HIV Integrase Inhibitors; 3.1 HIV: The Causative Agent of AIDS 3.1.1 Replication Cycle of HIV3.1.2 Highly Active Antiretroviral Therapy; 3.2 The Integration Step: A Complex Mechanism with Different Possibilities for Inhibition; 3.2.1 HIV-1 Integrase; 3.2.1.1 The Structural Organization of HIV-1 Integrase; 3.2.2 HIV-1 IN as a Target for HAART; 3.2.2.1 Integrase Strand Transfer Inhibitors; 3.2.2.2 Integrase Binding Inhibitors; 3.3 DNA Binding Inhibitors; 3.4 Multimerization Inhibitors; 3.5 Targeting Integrase Cofactor Interactions; 3.6 Conclusion; References; 4 From Saquinavir to Darunavir: The Impact of 10 Years of Medicinal Chemistry on a Lethal Disease 4.1 Introduction4.2 The HIV Protease as a Target for AIDS; 4.3 The Early Protease Inhibitors; 4.4 The Medical Need for a ""Next""-Generation PI; 4.5 How Can We Explain the Superior Antiviral Activity of Darunavir?; 4.6 Clinical Development of Darunavir; 4.7 Conclusions and Future Developments; References; 5 Acyclic and Cyclic Nucleoside Phosphonates; 5.1 Introduction; 5.2 Nucleoside Phosphonate Strategy for Antivirals; 5.3 Acyclic Nucleoside Phosphonates; 5.3.1 Main Classes and their Structure-Activity Relationships; 5.3.1.1 HPMP Analogues; 5.3.1.2 PME Analogues 5.3.1.3 PMP and FPMP Analogues |
| Record Nr. | UNINA-9910133657903321 |
| Weinheim, : Wiley-VCH, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral drug strategies / / edited by Erik De Clercq
| Antiviral drug strategies / / edited by Erik De Clercq |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2011 |
| Descrizione fisica | 1 online resource (428 p.) |
| Disciplina | 615.7/924 |
| Altri autori (Persone) | De ClercqErik |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico | Antiviral agents - Development |
| ISBN |
1-283-14091-8
9786613140913 3-527-63596-3 3-527-63597-1 3-527-63595-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antiviral Drug Strategies; Contents; List of Contributors; Preface; A Personal Foreword; 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug; 1.1 Introduction: The Prehistory; 1.2 Key Events in Antiviral Drug Development; 1.3 Antiviral Drugs: Current State of the Art; 1.4 Antiviral Drugs Active against Herpesviruses (i.e., HSV, VZV, and so on); 1.5 Antiviral Drugs Active against Retroviruses (HIV); 1.6 Antiviral Drugs Active against Hepatitis B Virus; 1.7 Antiviral Drugs Active against DNA Viruses at Large
1.8 Antiviral Drugs for Influenza A Virus Infections1.9 Antiviral Drugs for Hepatitis C Virus; 1.10 Antiviral Drugs for Poxviruses (i.e., Variola, Vaccinia, and so on); 1.11 Further Options to Treat Virus Infections; 1.12 Conclusions; References; 2 Inhibition of HIV Entry; 2.1 Introduction; 2.2 The HIV Glycoproteins; 2.2.1 Structure of the HIV-1 Glycoprotein gp120; 2.2.2 Structure of the HIV-1 Transmembrane Glycoprotein gp41; 2.3 Mechanism of HIV Entry; 2.3.1 Virus Attachment; 2.3.2 Coreceptors: Virus Tropism and Infectivity; 2.3.3 Virus-Cell Fusion; 2.3.4 Endocytosis of HIV 2.4 Inhibition of HIV Entry2.4.1 Inhibitors of Virus Attachment; 2.4.1.1 Polyanions as Inhibitors of HIV Attachment; 2.4.1.2 Small-Molecule Inhibitors of the gp120-CD4 Interaction; 2.4.2 Postattachment Inhibitors; 2.4.3 CCR5 Antagonists; 2.4.3.1 Maraviroc; 2.4.3.2 Vicriviroc; 2.4.3.3 Pro-140; 2.4.3.4 Resistance to CCR5 Antagonists; 2.4.4 CXCR4 Antagonists; 2.4.5 Inhibitors of HIV Fusion: Enfuvirtide; 2.5 Concluding Remarks; References; 3 Targeting Integration Beyond Strand Transfer: Development of Second-Generation HIV Integrase Inhibitors; 3.1 HIV: The Causative Agent of AIDS 3.1.1 Replication Cycle of HIV3.1.2 Highly Active Antiretroviral Therapy; 3.2 The Integration Step: A Complex Mechanism with Different Possibilities for Inhibition; 3.2.1 HIV-1 Integrase; 3.2.1.1 The Structural Organization of HIV-1 Integrase; 3.2.2 HIV-1 IN as a Target for HAART; 3.2.2.1 Integrase Strand Transfer Inhibitors; 3.2.2.2 Integrase Binding Inhibitors; 3.3 DNA Binding Inhibitors; 3.4 Multimerization Inhibitors; 3.5 Targeting Integrase Cofactor Interactions; 3.6 Conclusion; References; 4 From Saquinavir to Darunavir: The Impact of 10 Years of Medicinal Chemistry on a Lethal Disease 4.1 Introduction4.2 The HIV Protease as a Target for AIDS; 4.3 The Early Protease Inhibitors; 4.4 The Medical Need for a ""Next""-Generation PI; 4.5 How Can We Explain the Superior Antiviral Activity of Darunavir?; 4.6 Clinical Development of Darunavir; 4.7 Conclusions and Future Developments; References; 5 Acyclic and Cyclic Nucleoside Phosphonates; 5.1 Introduction; 5.2 Nucleoside Phosphonate Strategy for Antivirals; 5.3 Acyclic Nucleoside Phosphonates; 5.3.1 Main Classes and their Structure-Activity Relationships; 5.3.1.1 HPMP Analogues; 5.3.1.2 PME Analogues 5.3.1.3 PMP and FPMP Analogues |
| Record Nr. | UNINA-9910830144003321 |
| Weinheim, : Wiley-VCH, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral drug strategies / / edited by Erik De Clercq
| Antiviral drug strategies / / edited by Erik De Clercq |
| Pubbl/distr/stampa | Weinheim, : Wiley-VCH, c2011 |
| Descrizione fisica | 1 online resource (428 p.) |
| Disciplina | 615.7/924 |
| Altri autori (Persone) | De ClercqErik |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico | Antiviral agents - Development |
| ISBN |
1-283-14091-8
9786613140913 3-527-63596-3 3-527-63597-1 3-527-63595-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Antiviral Drug Strategies; Contents; List of Contributors; Preface; A Personal Foreword; 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug; 1.1 Introduction: The Prehistory; 1.2 Key Events in Antiviral Drug Development; 1.3 Antiviral Drugs: Current State of the Art; 1.4 Antiviral Drugs Active against Herpesviruses (i.e., HSV, VZV, and so on); 1.5 Antiviral Drugs Active against Retroviruses (HIV); 1.6 Antiviral Drugs Active against Hepatitis B Virus; 1.7 Antiviral Drugs Active against DNA Viruses at Large
1.8 Antiviral Drugs for Influenza A Virus Infections1.9 Antiviral Drugs for Hepatitis C Virus; 1.10 Antiviral Drugs for Poxviruses (i.e., Variola, Vaccinia, and so on); 1.11 Further Options to Treat Virus Infections; 1.12 Conclusions; References; 2 Inhibition of HIV Entry; 2.1 Introduction; 2.2 The HIV Glycoproteins; 2.2.1 Structure of the HIV-1 Glycoprotein gp120; 2.2.2 Structure of the HIV-1 Transmembrane Glycoprotein gp41; 2.3 Mechanism of HIV Entry; 2.3.1 Virus Attachment; 2.3.2 Coreceptors: Virus Tropism and Infectivity; 2.3.3 Virus-Cell Fusion; 2.3.4 Endocytosis of HIV 2.4 Inhibition of HIV Entry2.4.1 Inhibitors of Virus Attachment; 2.4.1.1 Polyanions as Inhibitors of HIV Attachment; 2.4.1.2 Small-Molecule Inhibitors of the gp120-CD4 Interaction; 2.4.2 Postattachment Inhibitors; 2.4.3 CCR5 Antagonists; 2.4.3.1 Maraviroc; 2.4.3.2 Vicriviroc; 2.4.3.3 Pro-140; 2.4.3.4 Resistance to CCR5 Antagonists; 2.4.4 CXCR4 Antagonists; 2.4.5 Inhibitors of HIV Fusion: Enfuvirtide; 2.5 Concluding Remarks; References; 3 Targeting Integration Beyond Strand Transfer: Development of Second-Generation HIV Integrase Inhibitors; 3.1 HIV: The Causative Agent of AIDS 3.1.1 Replication Cycle of HIV3.1.2 Highly Active Antiretroviral Therapy; 3.2 The Integration Step: A Complex Mechanism with Different Possibilities for Inhibition; 3.2.1 HIV-1 Integrase; 3.2.1.1 The Structural Organization of HIV-1 Integrase; 3.2.2 HIV-1 IN as a Target for HAART; 3.2.2.1 Integrase Strand Transfer Inhibitors; 3.2.2.2 Integrase Binding Inhibitors; 3.3 DNA Binding Inhibitors; 3.4 Multimerization Inhibitors; 3.5 Targeting Integrase Cofactor Interactions; 3.6 Conclusion; References; 4 From Saquinavir to Darunavir: The Impact of 10 Years of Medicinal Chemistry on a Lethal Disease 4.1 Introduction4.2 The HIV Protease as a Target for AIDS; 4.3 The Early Protease Inhibitors; 4.4 The Medical Need for a ""Next""-Generation PI; 4.5 How Can We Explain the Superior Antiviral Activity of Darunavir?; 4.6 Clinical Development of Darunavir; 4.7 Conclusions and Future Developments; References; 5 Acyclic and Cyclic Nucleoside Phosphonates; 5.1 Introduction; 5.2 Nucleoside Phosphonate Strategy for Antivirals; 5.3 Acyclic Nucleoside Phosphonates; 5.3.1 Main Classes and their Structure-Activity Relationships; 5.3.1.1 HPMP Analogues; 5.3.1.2 PME Analogues 5.3.1.3 PMP and FPMP Analogues |
| Record Nr. | UNINA-9910876726903321 |
| Weinheim, : Wiley-VCH, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
